about
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase geneIdentification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screeningSAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignanciesIdentification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based ApproachInteraction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspectsClass III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxelInactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicityStructural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analoguesSpatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast AgentsDrug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide.Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.Autoimmune thrombocytopenic purpura after autologous stem cell transplantation.Preparation, characterization and in vitro evaluation of a new nucleotide analogue prodrug cyclodextrin inclusion complexes.Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells.Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cellsPotent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein.Nucleoside analogues and nucleobases in cancer treatment.Nucleoside analogues: mechanisms of drug resistance and reversal strategies.Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.Wavelet-based decomposition of high resolution surface plasmon microscopy V(Z) curves at visible and near infrared wavelengths.Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes.Pyrimidine nucleoside analogs in cancer treatment.Cytosolic 5'-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf.Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma.Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).Regulation and activity of cytosolic 5'-nucleotidase II. A bifunctional allosteric enzyme of the Haloacid Dehalogenase superfamily involved in cellular metabolism.Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML PatientsPlasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
P50
Q24794747-08E135A5-76DF-419A-9078-7B02FACBDBDEQ27683573-E7603FEF-A715-4816-8880-1A07F46B050DQ27690846-8AA77BEB-7297-4BAC-A29D-3423CCFDDA9FQ27702875-8CD66881-D2BA-4F62-AB27-060F8FC2C5A1Q28202628-352A7A1B-5ABC-4015-9042-3468FD573314Q28287239-E908C8B8-6B10-4ABB-9FC9-CC272FA1D7F2Q28352698-5BC9A436-5B6E-4277-BEC4-DB7417E042C1Q28478308-E640DBA6-33C9-45AE-98D4-530E94409169Q30404719-DDCB175A-34FF-45FA-B181-4E0B1EBAF488Q30438642-0D5FABFA-474F-4FE9-8EFB-69DAF3009D6AQ31028788-90501754-9E73-41CF-A3E4-3EDE24DDA1B6Q31893686-B736D23B-8DA2-483D-917B-8106C3E3F1AAQ33337520-0751BDFB-D695-4E6C-A8C7-88785C02815EQ33348608-C07638B7-9076-4401-A3B7-D52B2098FCBAQ33445692-AF67D433-F104-4386-B253-949DA1B0747EQ33454122-84E79837-AECC-4A33-916E-9FED1897E3A7Q33506633-712ABE7D-0F08-40CF-9605-856528ACE502Q33552792-B949B60E-EEED-4B1E-B88A-2CF5757A52A8Q33669230-8E3CAF67-692C-4A8C-A9A9-E4DFCD1781ACQ34141323-E0A81058-0442-47C5-9171-90E88D0DF289Q34288371-8285AB11-55BB-4387-8095-0031DE7E555AQ34416847-C178B3D7-B900-49EB-B40B-24F55CBD20B1Q34594541-38620E13-F40F-43BC-84BC-EB52683163F6Q34643928-742C20FB-7ED6-41BC-8E8C-08EA00310C14Q34671809-6AD85E74-6F7D-40A6-8DB0-A3C92E5CE955Q34741021-EF0B1338-B0BF-4904-ACD6-908B4380982AQ34811676-5E3BBA40-D9D0-4FC5-9E88-94A8180C1274Q35223337-B34BE134-AC7B-42AD-869E-A0FF4F012F7DQ35548661-59464144-CC52-49FA-B6FC-266420AEEE70Q35576196-B8C78BA3-14A6-4C07-84E2-C4B065D6B349Q35587260-2286EB35-FCA1-4AD6-8C16-CDD60E3048C7Q35767684-3C6AEF48-632F-449B-80D6-AF1A9FF1D2BBQ35786749-C9996F1C-0DDC-450F-B44F-DD121A24F1F3Q35901915-AB3C4EB0-12C6-4B56-8F6F-95C0F69D22DFQ35994964-E5DAAAB7-D49C-4B8D-912F-6AADF2E41305Q36157351-7429EAD5-38D2-4A6E-B103-4F6C0416B4F4Q36254052-818628FD-DC9B-4B80-B29A-A4E29ADF2FB5Q36292902-6F77D917-DF88-4AB5-BD69-81E55AD428A3Q36682734-82C80BA0-A822-4E81-8E1D-8B4A6ABEC197Q36771977-B6ADA784-4292-4E9C-B5A6-F64BE9D1897B
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
C Dumontet
@ast
C Dumontet
@en
C Dumontet
@es
C Dumontet
@nl
type
label
C Dumontet
@ast
C Dumontet
@en
C Dumontet
@es
C Dumontet
@nl
prefLabel
C Dumontet
@ast
C Dumontet
@en
C Dumontet
@es
C Dumontet
@nl
P31
P496
0000-0003-1875-134X